CF PharmTech, Inc. (HKG:2652)
Hong Kong
· Delayed Price · Currency is HKD 21.70
-0.76 (-3.38%)
At close: Apr 29, 2026
CF PharmTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 432.52 | 607.75 | 556.42 | 349.13 | 41.99 | Upgrade
|
| Revenue Growth (YoY) | -28.83% | 9.22% | 59.38% | 731.54% | 764.11% | Upgrade
|
| Cost of Revenue | 104.58 | 117.67 | 101.85 | 83.46 | 21.78 | Upgrade
|
| Gross Profit | 327.94 | 490.09 | 454.57 | 265.67 | 20.2 | Upgrade
|
| Selling, General & Admin | 218.3 | 363.37 | 319.93 | 243.81 | 138.88 | Upgrade
|
| Research & Development | 124.55 | 121.85 | 132.79 | 107.23 | 98.46 | Upgrade
|
| Other Operating Expenses | -0.1 | - | - | - | 0.77 | Upgrade
|
| Operating Expenses | 348.08 | 486.51 | 452.4 | 351.45 | 238.1 | Upgrade
|
| Operating Income | -20.15 | 3.58 | 2.17 | -85.78 | -217.9 | Upgrade
|
| Interest Expense | -2.54 | -1.78 | -0.17 | -0.16 | -0.14 | Upgrade
|
| Interest & Investment Income | 2.15 | 0.61 | 3.92 | 4.29 | 20.71 | Upgrade
|
| Earnings From Equity Investments | -0.17 | -0.07 | -0.1 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.2 | 2.5 | -1.76 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.06 | 16.85 | 16.82 | 8.54 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -16.65 | 19.18 | 22.44 | -70.62 | -199.18 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.24 | - | - | - | 0.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | -0.02 | Upgrade
|
| Other Unusual Items | - | - | - | - | 4.57 | Upgrade
|
| Pretax Income | -13.41 | 19.18 | 22.44 | -70.62 | -194.2 | Upgrade
|
| Income Tax Expense | -15.89 | -1.9 | -9.28 | -21.22 | -62.47 | Upgrade
|
| Net Income | 2.49 | 21.09 | 31.73 | -49.4 | -131.73 | Upgrade
|
| Net Income to Common | 2.49 | 21.09 | 31.73 | -49.4 | -131.73 | Upgrade
|
| Net Income Growth | -88.22% | -33.53% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 378 | 371 | 371 | 371 | - | Upgrade
|
| Shares Outstanding (Diluted) | 378 | 371 | 371 | 371 | - | Upgrade
|
| Shares Change (YoY) | 1.85% | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.01 | 0.06 | 0.09 | -0.13 | - | Upgrade
|
| EPS (Diluted) | 0.01 | 0.06 | 0.09 | -0.13 | - | Upgrade
|
| EPS Growth | -88.43% | -33.53% | - | - | - | Upgrade
|
| Free Cash Flow | - | -71.2 | 1.65 | -45.72 | -247.95 | Upgrade
|
| Free Cash Flow Per Share | - | -0.19 | 0.00 | -0.12 | - | Upgrade
|
| Gross Margin | 75.82% | 80.64% | 81.69% | 76.09% | 48.12% | Upgrade
|
| Operating Margin | -4.66% | 0.59% | 0.39% | -24.57% | -518.98% | Upgrade
|
| Profit Margin | 0.57% | 3.47% | 5.70% | -14.15% | -313.74% | Upgrade
|
| Free Cash Flow Margin | - | -11.72% | 0.30% | -13.10% | -590.55% | Upgrade
|
| EBITDA | 33.55 | 57.27 | 50.53 | -51.53 | -191.71 | Upgrade
|
| EBITDA Margin | 7.76% | 9.42% | 9.08% | -14.76% | - | Upgrade
|
| D&A For EBITDA | 53.69 | 53.69 | 48.37 | 34.25 | 26.19 | Upgrade
|
| EBIT | -20.15 | 3.58 | 2.17 | -85.78 | -217.9 | Upgrade
|
| EBIT Margin | -4.66% | 0.59% | 0.39% | -24.57% | - | Upgrade
|
| Advertising Expenses | - | 181.7 | 165.59 | 93.59 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.